$162 Million is the total value of ARCH Venture Management, LLC's 6 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EQRX, INC. | $67,583,798 | -4.1% | 36,335,375 | 0.0% | 41.73% | +22.7% | ||
| VERV | VERVE THERAPEUTICS, INC. | $37,665,169 | +30.0% | 2,008,809 | 0.0% | 23.26% | +66.3% | |
| ERASCA, INC. | $30,513,329 | -8.3% | 11,055,554 | 0.0% | 18.84% | +17.3% | ||
| OMIC | SINGULAR GENOMICS SYSTEMS, INC. | $3,153,109 | -31.4% | 3,798,926 | 0.0% | 1.95% | -12.3% | |
| UNITY BIOTECHNOLOGY, INC. | $2,562,283 | +56.4% | 1,004,817 | 0.0% | 1.58% | +100.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| RUBIUS THERAPEUTICS, INC. | 12 | Q3 2022 | 65.5% |
| EQRX, INC. | 8 | Q3 2023 | 52.4% |
| ERASCA, INC. | 8 | Q3 2023 | 18.8% |
| VERVE THERAPEUTICS, INC. | 8 | Q3 2023 | 23.3% |
| CHIASMA INC | 8 | Q3 2020 | 25.7% |
| SINGULAR GENOMICS SYSTEMS, INC. | 8 | Q3 2023 | 4.6% |
| KURA ONCOLOGY INC | 7 | Q2 2020 | 27.6% |
| KARUNA THERAPEUTICS, INC. | 6 | Q1 2023 | 52.8% |
| DENALI THERAPEUTICS, INC. | 6 | Q3 2023 | 28.6% |
| SYROS PHARMACEUTICALS INC | 5 | Q3 2020 | 43.8% |
View ARCH Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-15 |
| 13F-HR/A | 2022-05-27 |
| 13F-HR | 2022-05-13 |
View ARCH Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.